Objective-To characterize the expression and function of interleukin (IL) 19, a recently described T-helper 2 anti-inflammatory IL, on endothelial cell (EC) pathophysiological features. Methods and Results-The expression and effects of anti-inflammatory ILs on EC activation and development of angiogenesis are uncharacterized. We demonstrate by immunohistochemistry and immunoblot that IL-19 is expressed in inflamed, but not normal, human coronary endothelium and can be induced in cultured human ECs by serum and basic fibroblast growth factor. IL-19 is mitogenic and chemotactic, and it promotes EC spreading. IL-19 activates the signaling proteins STAT3, p44/42, and Rac1. In functional ex vivo studies, IL-19 promotes cordlike structure formation of cultured ECs and enhances microvessel sprouting in the mouse aortic ring assay. IL-19 induces tube formation in gelatinous protein (Matrigel) plugs in vivo. Conclusion-To our knowledge, these data are the first to report expression of the anti-inflammatory agent, in ECs; and the first to indicate that IL-19 is mitogenic and chemotactic for ECs and can induce the angiogenic potential of ECs. (Arterioscler Thromb Vasc Biol. 2011;31:167-175.)
can result in migration and proliferation and is an essential component of multiple normal and pathophysiological processes, including atherosclerosis, permeability, wound healing, and angiogenesis. [1] [2] [3] Angiogenesis is the growth of new blood vessels and normally occurs in the process of healing wounds and restoring blood flow after injury or insult. The expressions of both inflammatory and antiinflammatory cytokines participate in wound healing and neovascularization, and many proinflammatory cytokines play an established role in angiogenesis. For example, proinflammatory cytokines (ie, interleukin [IL] 1␤, IL-8, and IL-18) promote angiogenesis with direct increased effects on EC migration, proliferation, matrix metalloproteinase production, tube formation; and vascularity in vivo. 4 -6 Although it may be intuitive that the inflammatory state of ischemic tissue may dictate whether that tissue is neovascularized or becomes necrotic, the role and direct effects of antiinflammatory ILs on ECs in initiation and progression of neovascularization are less clear and are somewhat inconsistent. For example, it is recognized that the M2 antiinflammatory macrophage phenotype promotes tissue regeneration and angiogenesis by secretion of soluble factors. However, the prototypical anti-inflammatory cytokine, IL-10, has antiangiogenic activity and is associated with vascular endothelial growth factor (VEGF) downregulation and reduc-tion of fibroblast growth factor (FGF)-and VEGF-induced proliferation of microvascular ECs. 7 IL-10 also induced tissue inhibitor of metalloproteinase 1 (TIMP1) and reduced matrix metalloproteinase 2 production in ECs. 8 IL-4 can inhibit VEGF production and reduce vascularization; it can also induce migration and tubelike structure formation in ECs, activities consistent with angiogenesis. 9 -11 IL-20 also has reported proangiogenic and antiangiogenic effects. [12] [13] [14] The identification of cytokines and their receptors (common to leukocytes and ECs) has the potential to link inflammatory and angiogenic processes. Characterization of these molecules and their function in these processes could lead to new therapies for tissue repair and neovascularization; this requires further investigation. IL-19 is an IL-10 family member expressed in monocytes and T and B lymphocytes and can be upregulated in these cells by lipopolysaccharide and granulocyte colonystimulating factor. [15] [16] [17] [18] Like IL-10, IL-19 has been ascribed to be a T-helper 2 (Th2) anti-inflammatory IL. 18 Treatment of maturing antigen-presenting cells with IL-19 promotes the Th2 (regulatory), rather than the Th1, response; and induces IL-10, and decreases interferon-␥, expression in T cells. 17, 18 The expression and function of anti-inflammatory ILs on EC pathophysiological features remain uncharacterized; to our knowledge, the role of IL-19 in particular in wound healing or neovascularization has not been reported. To test the hypoth-esis that IL-19 has a non-Th2 regulatory function in ECs, we designed experiments to determine a role for this IL in EC activation and angiogenesis. This is an inaugural study describing IL-19 effects in ECs, and there are several unique findings in this report. We report that IL-19 expression can be induced in cultured ECs and can activate multiple signal transduction proteins. The IL-20 receptor, the receptor for IL-19, is expressed on ECs. IL-19 is mitogenic for ECs; IL-19 also promotes tubelike structure formation on gelatinous protein (Matrigel) by ECs and microvessel formation in the mouse aortic ring assay and in vivo in Matrigel plugs. Because it is expressed by both leukocytes and ECs, we propose that IL-19 be considered an inducible mediator of leukocyte/EC bidirectional communication in regulation of tissue repair and vessel regeneration. This has important implications for the role of anti-inflammatory factors in general in the promotion of wound healing and vascular inflammation.
Methods

Immunohistochemistry
Human coronary arteries were removed from nonfailing hearts from organ donors that were deemed not appropriate for transplantation and hearts that needed to be removed from patients with severe coronary artery transplant vasculopathy (CAV) at retransplantation and processed as previously described. 19 Cell culture, cell proliferation, migration assays, Rac1 activation, Western blotting, cordlike structure analysis, flow cytometry, aortic ring assay, RT-PCR, mouse Matrigel plug, and statistical analysis were all performed as previously described. 19 All animal procedures were approved by the Institutional Animal Care and Use Committee of Temple University, Philadelphia, Pa.
Cell Spreading
Spreading was performed as described and calculated by tracing the cell and measuring the area using computer software (Image-Pro Plus). 20 The supplemental material (available online at http://atvb. ahajournals.org) provides further details on the methods.
Results
ECs Express IL-19
Immunohistochemical staining of healthy and diseased human coronary arteries established IL-19 expression in human endothelium. Figure 1A demonstrates that IL-19 is expressed in ECs in human coronary arteries with CAV, a disease in which endothelium is continuously inflamed. Previously, it was shown that IL-19 is expressed in some smooth muscle cells and CD45-positive cells in inflamed arteries. 21 IL-19 immunoreactivity in endothelium in arteries with CAV was confirmed by colocalization with the EC marker von Willebrand factor ( Figure 1B) . In contrast, healthy control coronary arteries did not show any expression of IL-19 in endothelium or other medial cells. Because CAV arteries exist in a milieu of cytokines and growth factors, we performed experiments to investigate differential expression of IL-19 by cytokines in cultured ECs under more defined conditions. Human vascular ECs (HVECs), coronary artery ECs (CaECs), and coronary micro-ECs (mECs) were cultured in serum-reduced media for 24 hours; and then stimulated with a variety of soluble factors. Figure 1C shows that all cultured ECs express basal levels of IL-19 protein but can be induced to express significantly increased IL-19 (ϫ10% FCS and basic FGF (bFGF); PϽ0.05; nϭ3 experiments) (supplemental Figure I ). Other factors can also increase IL-19 expression, but not to a significant degree. Expression of IL-19 mRNA mirrors protein expression (data not shown). These data are the first to indicate that IL-19 expression is inducible in several EC types. Subsequent experiments were focused to determine a function and potential mechanism of IL-19 activity in ECs. Figure II ). IL-19 signals through the IL-20 receptor, which is composed of ␣ and ␤ subunits and is known to activate STAT proteins. Each EC type expressed detectible amounts of mRNA for each of the IL-20 receptor subunits (supplemental Figure III) .
IL-19 Activates EC Signal Transduction and Enhances Proliferation
Because activation of p44/42 MAPK participates in EC mitogenesis, we tested the hypothesis that IL-19 could promote proliferation of ECs by itself and/or enhance VEGFor bFGF-mediated EC proliferation. HVECs, CaECs, and mECs cultured in growth media were treated with IL-19 (100 ng/mL); at 1, 3, and 5 days, they were trypsinized and counted. In each EC type, IL-19 significantly increased EC proliferation at 5 days: 43.7Ϯ1.6 versus 27.8Ϯ1.4, 38.4Ϯ1.3 versus 26.3Ϯ1.5, and 23.9Ϯ1.8 versus 15.0Ϯ1.3 ECs/mL for HVECs, CaECs, and mECs, respectively (PϽ0.001 for all) ( Figure 2E ). This is not because of decreased apoptosis of these cells, as ascertained by annexin V staining (supplemental Figure IV ). IL-19 did not induce VEGF or bFGF protein expression (supplemental Figure V) nor enhance either VEGF-or bFGF-mediated HVEC proliferation (supplemental Figure VI ). To determine whether IL-19 proliferative effects are contingent on p44/42 MAPK activity, each EC type was cultured in the presence of 2 different MAPK inhibitors (PD98059 or U0126). Each of these inhibitors, at published median effective concentrations (5 mol/L each), significantly reduced IL-19 -driven EC proliferation in the range of 23.3% to 66.0% (PϽ0.01 for each EC type) ( Figure 2F ). This indicates that IL-19 is mitogenic for multiple EC types and uses the p44/42 MAPK pathway in this process.
IL-19 Activates EC Spreading and Migration
p44/42 MAPK, Rac1, and STAT3 regulate cytoskeletal organization and actin dynamics; we hypothesized that IL-19 would influence EC spreading and/or migration. In all 3 EC types, compared with unstimulated cells, IL-19 significantly enhanced cell spreading: 3060Ϯ110 versus 4650Ϯ110, 2620Ϯ 170 versus 4087Ϯ190, and 203Ϯ120 versus 4260Ϯ290 m 2 for HVECs, CaECs, and mECs, respectively (PϽ0.001) ( Figure 3A and 3B).
To determine whether IL-19 induced EC migration, HVECs were seeded onto the top chamber in medium containing 0.2% BSA, with or without 100-ng/mL IL-19, or VEGF as a positive control, in the lower chamber. Some ECs were pretreated with IL-19 for 16 hours before trypsinization and seeding in migration chambers. Figure 3C shows that the addition of IL-19 significantly increases HVEC migration (107.5Ϯ19.3 compared with 357.6Ϯ29.9 ECs/high-power field [HPF] for unstimulated versus IL-19 treated; PϽ0.01, nϭ3), which is comparable to values obtained for VEGF (317.0Ϯ36.9 ECs/HPF); also, there was no significant difference between IL-19 -and VEGF-treated HVECs. Interestingly, coincubation of VEGF and IL-19 resulted in significantly more migration than VEGF alone (503.1Ϯ26.4 versus 317.0Ϯ36.9 ECs/HPF for combined versus VEGF; PϽ0.05). Also, ECs preincubated with IL-19 before seeding in the chamber, which did not have IL-19 in the lower chamber, also migrated significantly more rapidly than VEGF alone (447.3Ϯ24.3 versus 317.0Ϯ36.9 ECs/HPF for pretreated versus unstimulated ECs; PϽ0.5; nϭ3) ( Figure 3D ). There was no statistical difference in migration between HVECs that had VEGF and IL-19 in the lower chamber and those that were pretreated with IL-19 but only had VEGF in the lower chamber. Experiments were also performed in which IL-19 neutralizing antibody was added to the lower chamber. Figure  3B shows that IL-19 neutralizing antibody significantly reduced IL-19 -induced HVEC migration at all concentrations of neutralizing antibody used. VEGF does not induce IL-19 expression (supplemental Figure VII) nor does IL-19 neutralizing antibody reduce VEGF-induced migration (supplemental Figure VIII ). Together, these data are the first to show that IL-19 stimulates EC signaling, spreading, and migration.
IL-19 Promotes EC Cordlike Structure Formation
We hypothesized that IL-19 might play a role in endothelial migration and organization, leading to tubelike or cordlike structure formation. HVECs were seeded onto growth factorreduced Matrigel, in the presence of 10% FCS. Some HVECs were treated with IL-19, some were cotreated with IL-19 and VEGF, and some were pretreated with IL-19 and then treated with VEGF or with VEGF alone as a positive control. The number of cordlike structures was counted manually per multiple representative images, and an average was calculated for each condition. Data presented in Figure 4 show that IL-19 can induce significantly more cordlike structures than control samples ( 
IL-19 Promotes Microvessel Formation
Because IL-19 effected cordlike structure formation, we hypothesized that IL-19 could also regulate EC sprouting using 2 independent assays: ex vivo from aortic rings and in vivo using the Matrigel plug angiogenesis assay. 22, 23 Mouse thoracic aorta was sectioned, placed onto growth factorreduced Matrigel, and incubated in media containing IL-19, PBS, or VEGF as a positive control. Sprouting from rings was analyzed daily; on the sixth day, it was photographed and the outgrowth area was quantified by image analysis. Figure  5 shows that aortic rings incubated with IL-19 showed significantly greater sprouting area than Matrigel alone (770.0Ϯ85.1 versus 1877.3Ϯ48.1 m 2 for unstimulated versus IL-19 treated; PϽ0.01; nϭ6). This was similar to values for the VEGF-positive control and rings incubated with both IL-19 and VEGF (1784.8Ϯ28.8 and 1730.0Ϯ478.0 m 2 for VEGF and IL-19 and VEGF cotreated, respectively). Immunostaining was performed on whole mounts of aortic rings. Sprouting microvessels were immunoreactive with plateletendothelial cell adhesion molecule 1 (PECAM1) antibody, demonstrating the presence of ECs in these structures.
To determine whether IL-19 could stimulate microvessel formation in vivo, 0.5 mL of growth factor-free Matrigel was mixed with 200 ng of IL-19, 200 ng of VEGF, or PBS control; and delivered as a single plug subcutaneously. After 10 days, the plug was recovered and microvessels containing lumen were determined by immunohistochemistry using PECAM1 antibody. Figure 6 shows that Matrigel containing IL-19 had significantly more PECAM1-positive microvessels per unit area than did PBS control plugs (2.5Ϯ0.08, 6.9Ϯ1.0, and 12.8Ϯ2.1 microvessels per unit area for PBS, IL-19, and VEGF, respectively; PϽ0.05). These PECAM1-positive structures surrounded a lumen, indicating that IL-19 can induce microvessel formation in vivo.
Discussion
The major finding of this study is that IL-19 is a novel proangiogenic factor expressed in ECs. IL-19 is a Th2 anti-inflammatory IL, and nothing has been reported on the expression or mechanism(s) of IL-19 effects on ECs. Basal levels of IL-19 can be detected in human monocytes and B and T lymphocytes, and IL-19 expression can be upregulated in these cells by stimulation. To our knowledge, this is the first report regarding IL-19 expression in ECs, and IL-19 expression in inflamed ECs suggests a role distinct from Th1/Th2 phenotype modulation in lymphocytes. The observation that low basal levels of IL-19 expression can be increased by FCS is consistent with the finding that IL-19 is undetectable in uninjured human arteries but is increased in arteries from patients diagnosed as having CAV, a chronic inflammatory disease in allografted hearts. Expression in injured arteries is also consistent with an in vivo murine tissue survey indicating that IL-19 is not present in unstimulated tissue but can be induced in immune and local tissue cells in inflamed tissue and cultured keratinocytes when stimulated with IL-1␤. 24, 25 The expression of certain antiinflammatory cytokines (ie, IL-9, IL-10, or IL-11) in ECs has not been reported. However, IL-4 is detected in ECs from atherosclerotic plaques and can increase vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, and IL-6 levels, consistent with a proinflammatory effect on endothelium. 11, 26 IL-19 shares 20% amino acid identity with IL-10 but does not engage the IL-10 receptor; rather, it engages the IL-20 receptor, which is known to activate STAT proteins in several cell types. 17, 27 In our study in HVECs, IL-19 did activate both STAT3 and p44/42 MAPK activity, but not STAT1. There is a diversity in use of various members of the STAT family by ILs, much of which is regulated by tissue-specific expression of receptor subunits. 27, 28 The IL-20 receptor is composed of ␣ and ␤ subunits; this study shows that each EC type examined expressed both IL-20 receptor chains. IL-19 can only engage and signal through a heterodimer of ␣ and ␤ chains. 16, 17, 24 In another study in ECs, IL-20 also activated p44/42; however, it activated STAT1 rather than STAT3. 12 Interestingly, IL-20 stimulated STAT3 in keratinocytes. 27 Some of these differences in signaling and gene expression may be explained by IL-20 receptor complexity and tissue distribution. 27, 29 The present study demonstrated that IL-19 was capable of meditating EC spreading and migration and proliferation. STAT3, p44/42, and the small GTPase Rac1 are involved in EC proliferation, migration, and angiogenesis. STAT3 in particular participates in angiogenesis by multiple mechanisms, including potentiation of microtubule polymerization, leading to increased migration and induction of VEGF expression. 30, 31 p44/42 regulates membrane protrusions and focal adhesion dynamics, and specific p44/42 inhibitors decrease migration of multiple cell types, including ECs. 32, 33 Rac1 also has a key role in cell migration by influencing actin cytoskeleton and membrane ruffling, and IL-19 activation of any 1 of these 3 enzymes may be responsible for EC spreading and migration. 34, 35 Interestingly, ECs pretreated with IL-19 for 24 hours migrated more rapidly than those singly incubated with either IL-19 or VEGF and migrated to the same degree as those coincubated with both VEGF and IL-19 as chemotactic agents in the lower chamber, suggesting that IL-19 could induce expression of a factor(s) that played a part in migration.
Migration and proliferation of ECs in response to peptide factors are key events in angiogenesis. IL-19 promoted cordlike structure formation on Matrigel by human umbilical vein ECs, enhanced microvessel formation in isolated mouse aortic rings, and enhanced microvessel formation in Matrigel plugs in vivo. PECAM1-positive structures in Matrigel plugs surrounded a lumen. These assays assess EC migration, proliferation, differentiation, and polarization of primary quiescent ECs into organized sprouts. Microvessels sprouting from aortic rings were immunoreactive with PECAM1 antibody, confirming the effects of IL-19 on ECs in these structures.
Various proinflammatory ILs (eg, IL-1, IL-8, IL-17, and IL-20) were identified as angiogenic; they increase EC migration, cordlike structure organization, and matrix metalloproteinase production. 4 -6,36 However, the effects of anti- inflammatory ILs on angiogenesis are not well characterized.
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The archetypal anti-inflammatory cytokine, IL-10, is antiangiogenic because it reduces EC migration and downregulates VEGF production. 7, 8 Although IL-4 is antiangiogenic in that it inhibits VEGF production and reduces vascularization, 10, 37 it can also induce migration and cordlike structure formation in ECs, consistent with angiogenesis. 9, 11 Similarly, IL-13 attenuates EC tube formation by induction of the JAK2-STAT6 pathway. 38 IL-20 is expressed by ECs and has both proangiogenic and antiangiogenic effects on ECs. 12 antiproliferative effects in both a breast cancer cell line and human vascular smooth muscle cells. 17, 21 This may also be a function of tissue-specific expression of receptor subunits, and distribution of receptor chain expression on ECs and vascular smooth muscle cells requires further investigation. The notion that a Th2 anti-inflammatory IL can directly regulate EC pathophysiological features is novel and has important implications for the role of anti-inflammatory mediators in vasculogenesis. This is an inaugural study describing IL-19 effects in ECs, and there are several unique findings in this report. The expression of IL-19, a Th2 IL, can be induced in cultured ECs and in vivo by local inflammation. Treatment of cultured human ECs with IL-19 results in activation of STAT3, p44/42 MAPK, and Rac1. IL-19 treatment of ECs results in increased cell spreading and enhanced migration. IL-19 is mitogenic for ECs and enhances cordlike structure formation and microvessel sprouting from aortic rings. IL-19 can induce microvessel formation in Matrigel plugs in vivo. Angiogenesis is a multistep process requiring EC activation, basement membrane degradation, proliferation, migration, and cord formation. This study suggests that IL-19 can participate in each of these processes and has important implications for wound healing, vasculogenesis, and vascular biology. 
